Insulin is not needed for glucose to enter cells (the HbA1c inside red blood cells proves it); insulin therefore does not treat diabetes but 'starves' cells, especially the brain, of sugar.
Original statement
الانسولين ضروري لدخول السكر سكر في الخلايا غلط والدليل ان التراكمي جوه الخليه
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Insulin is not needed for glucose to enter cells (the HbA1c inside red blood cells proves it); insulin therefore does not treat diabetes but 'starves' cells, especially the brain, of sugar.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! لايف منتظر (Open source)
- Published
- 8 February 2026
- Timestamp
- 0:15:57 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
- Claimed mechanism
Glucose enters red blood cells and brain cells without insulin; insulin pushes glucose into storage and away from the brain.
- Claimed health effect
Insulin starves cells; insulin is useless as therapy
- Population concerned
People with diabetes
- Geographic restriction by Elawady
none found
Diverging source versions
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- ارتفاع السكر والأسيتون ؟خطر والا ده الطبيعي ؟#ضياء_العوضي (Open source)
- Published
- 23 December 2025
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- المفاهيم المضللة عن الإنسولين ومغالطات شائعه حول الإنسولين #ضياء_العوضي (Open source)
- Published
- 17 April 2026
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Insulin is not needed for glucose uptake, so it does not treat anything and starves cells.
2. What is demonstrably correct?
Glucose uptake into red blood cells and brain does not require insulin; glycated haemoglobin forms inside red cells without insulin. Too much insulin causes hypoglycaemia, which deprives the brain of glucose (A-INS-14, A-INS-15).
3. What is wrong or exaggerated?
Muscle (the largest glucose sink after meals) and fat tissue need insulin for glucose uptake; the liver needs insulin signals to stop releasing glucose and producing ketones. That is why absolute insulin deficiency (type 1 diabetes) causes high glucose, ketoacidosis and weight loss despite eating. HbA1c is a valid measure of average glucose exposure and predicts complications (I-INS-04). Insulin therapy lowers glucose and complications in RCTs (I-INS-03, A-INS-16). The claim that 'no drug on earth lowers sugar' is contradicted by every glucose-lowering trial cited by the archive itself.
4. What remains unclear?
When insulin 'does not work' in practice, causes such as injection into lipohypertrophic tissue (blunted and variable absorption, A-INS-20), insulin resistance or omitted doses should be considered; they do not show that insulin is ineffective.
5. Which studies support it?
Physiology of insulin-independent glucose transporters (kernel only).
6. Which studies contradict it?
I-INS-03, I-INS-04, A-INS-16, I-INS-07, I-INS-104 (intensive insulin therapy associated with lower long-term mortality), I-INS-116 (insulin withdrawal lowers muscle ATP production and raises ketones), I-INS-133, I-INTB-01.
7. What applies to Germany and Europe?
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. What is known about Egypt?
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. What practical conclusion is appropriate?
The fact that some cells take up glucose without insulin does not make insulin unnecessary; people who need insulin must keep taking it.
Assessment details
- Rationale for certainty of evidence
Correct kernel: red blood cells, brain and liver take up glucose largely independent of insulin (GLUT1/GLUT3/GLUT2), and HbA1c forms inside red cells without insulin. Wrong conclusion: skeletal muscle and fat depend on insulin (GLUT4); insulin also suppresses liver glucose and ketone production; insulin deficiency leads to ketoacidosis and death (type 1 diabetes). Insulin's efficacy is shown in RCTs (DCCT, UKPDS).
- Source quality
Own words, several machine transcripts.
- Regional transferability
Universal.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).
Research question: Is insulin unnecessary for glucose uptake, so that insulin therapy does not treat diabetes but starves cells?
Research question in detail (PECO)
- Population
- People with diabetes
- Intervention or exposure
- Insulin action/therapy
- Comparison
- Insulin deficiency
- Geographic scope
- universal biology
- Outcomes
- Glucose uptake by tissues
- Ketosis
- Clinical outcomes of insulin therapy
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Severe low blood sugar and death in ACCORD
Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909 Cohort studyfull text, structured risk-of-bias assessmentSevere hypoglycaemia from glucose-lowering therapy is associated with mortality.
- Actual result
- aHR 1.41-2.30.
- Methodological quality
- moderate
- Relevance
- indirect: excess insulin can deprive the brain of glucose
- Limitations
- Concerns overdosing, not normal therapy.
What speaks against the claim?
DCCT: better insulin treatment in type 1 diabetes
Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401 Randomised controlled trialabstract checkedDCCT: insulin therapy reduces complications.
- Actual result
- Retinopathy -76%.
- Methodological quality
- high
- Relevance
- direct
Long-term survival after intensive insulin treatment in type 1 diabetes
Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107 Randomised controlled trialabstract checkednewly addedDCCT/EDIC: intensive insulin therapy and long-term mortality.
- Actual result
- HR 0.67 (0.46-0.99).
- Methodological quality
- high (randomised origin)
- Relevance
- direct
- Limitations
- Borderline CI.
What happens to muscle energy when insulin is withheld in type 1 diabetes
Karakelides H et al.. Diabetes 2007 · PMID 17660267 · DOI 10.2337/db07-0378 Otherabstract checkednewly addedInsulin withdrawal in T1D reduces muscle ATP production and raises ketones.
- Actual result
- Decreased mitochondrial ATP production.
- Methodological quality
- moderate
- Relevance
- direct
- Limitations
- n=9.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Some tissues (brain, red cells) take up glucose without insulin, but muscle and fat need insulin, and insulin suppresses hepatic glucose and ketone output; insulin therapy lowers complications and mortality.
Why some studies weigh more
RCTs and physiology outweigh the correct but misapplied kernel.
Is a causal relationship established? Yes, established Insulin deficiency causes hyperglycaemia and ketoacidosis; insulin reverses them.
Remaining uncertainty
None material.
Justified conclusion
Mostly false: true kernel, wrong conclusion.
Does this depend on the country?
- General biological effects
- Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
- Eating habits
- Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
- Actual monitoring data
- Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Crude mortality by arm – 6.0% vs 8.8% recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Clinical efficacy of insulin therapy in insulin-deficient diabetes
- Starting level
- high (randomised trials)
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- ADA/EASD: The management of type 1 diabetes in adults: updated 2026 consensus report (2026) · Original publication
'Lifelong insulin therapy is essential in type 1 diabetes'; all individuals need glucose and ketone testing supplies; insulin omission or under-dosing is a DKA precipitant. - ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (I-ODD-16) (2026) · Original publication
'Insulin treatment is essential for individuals with type 1 diabetes'; insulin to be considered in T2D when A1C >10%, glucose >=300 mg/dL or catabolic features (as recorded for I-ODD-16). - ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · Original publication
People at risk for DKA should have ketone testing tools and sick-day advice; people on intensive insulin therapy should not stop or hold basal insulin even if not eating; caution with near-normal A1C goals in long-standing T2D using hypoglycaemia-prone drugs (ACCORD).
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| PubMed | 26 October 2026 | (brain glucose uptake OR cerebral glucose metabolism) AND (insulin-independent OR "independent of insulin") AND human | supporting evidence | 513 | |
| Europe PMC | 26 October 2026 | (TITLE:"red blood cell" OR TITLE:"erythrocyte") AND (TITLE:"glucose uptake" OR TITLE:"GLUT1") AND insulin | supporting evidence | 4 | |
| Europe PMC | 26 October 2026 | (TITLE:"insulin") AND (TITLE:"brain" OR TITLE:"cerebral") AND (TITLE:"glucose uptake") AND human | supporting evidence | 8 | |
| PubMed | 26 October 2026 | DeFronzo RA[au] AND "disposal of intravenous glucose" | contradicting evidence | 19 | |
| PubMed | 26 October 2026 | (GLUT4 OR "skeletal muscle") AND "insulin-stimulated glucose uptake" AND human AND review[pt] | contradicting evidence | 80 | |
| PubMed | 26 October 2026 | "insulin deprivation" AND mitochondrial AND ATP AND "type 1 diabetes" | contradicting evidence | 2 | |
| PubMed | 26 October 2026 | DCCT EDIC AND mortality AND JAMA[ta] AND 2015[dp] | contradicting evidence | 1 |
How deeply was this checked?
11 linked studies: 4 checked in full text (2 of them with a structured risk-of-bias assessment), 7 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (high)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly false (high)
New evidence (DCCT/EDIC mortality, insulin-withdrawal physiology) strengthens the existing assessment; the insulin-independent glucose uptake kernel remains correct.
New sources: I-INS-104 I-INS-116 I-INS-133
In plain language
It is true that the brain and red blood cells can take up sugar without insulin. But muscles and fat tissue need insulin, and insulin also tells the liver to stop pouring sugar and acids into the blood. People who make no insulin become very ill even though their brains can take up sugar. Insulin therapy has been proven in trials to lower sugar and prevent complications.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (8)
-
DCCT: better insulin treatment in type 1 diabetes
Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401Randomised controlled trialindependent cross-checkabstract checked★ key studyIntensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does intensive insulin therapy reduce long-term complications in type 1 diabetes?
- How was the study done?
Multicentre RCT (DCCT)
- How many people, animals or samples were studied?
1,441; Insulin-dependent (type 1) diabetes
- What was actually found?
Large reductions in all microvascular complications.
- How large was the observed effect?
Retinopathy -76%
- What do the results mean in everyday life?
Insulin protects eyes, kidneys and nerves in type 1 diabetes.
- What are the study's limitations?
Open-label; Selected young population
- What does it say about Elawady's specific claim?
Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).
- Do the results apply to Germany and Europe?
North American; universally accepted.
- What can explicitly not be concluded from this study?
Effects in type 2 diabetes directly.
-
How much long-term blood sugar matters (UKPDS 35)
Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405Cohort studyindependent cross-checkabstract checked★ key studyEach 1% lower HbA1c was linked to 21% fewer diabetes deaths and 37% fewer eye/kidney complications.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Relation of glycaemia over time to complications
- How was the study done?
Prospective observational analysis within UKPDS (UKPDS 35)
- How many people, animals or samples were studied?
4,585 (3,642 for RR); UKPDS patients (white, Asian Indian, Afro-Caribbean)
- What was actually found?
Graded risk with HbA1c, no threshold.
- How large was the observed effect?
-21% per 1% HbA1c
- What do the results mean in everyday life?
High sugar damages the body.
- What are the study's limitations?
Observational
- What does it say about Elawady's specific claim?
Contradicts C-DIAB-01, C-DIAB-02, C-ODD-06 (hyperglycaemia causes complications incl. amputation).
- Do the results apply to Germany and Europe?
UK.
- What can explicitly not be concluded from this study?
That pushing HbA1c to normal is always safe.
-
UKPDS: tablets or insulin for new type 2 diabetes
UKPDS Group. Lancet 1998 · PMID 9742976Randomised controlled trialcited by the Tayebat archiveabstract checked★ key studyBetter sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Intensive control with sulfonylurea or insulin vs diet on complications
- How was the study done?
Multicentre RCT (UKPDS 33)
- How many people, animals or samples were studied?
3,867; Newly diagnosed type 2 diabetes, median age 54
- What was actually found?
Microvascular -25%; more hypoglycaemia and weight gain with insulin.
- How large was the observed effect?
RR reduction 25% microvascular
- What do the results mean in everyday life?
Insulin helps prevent complications but has side effects.
- What are the study's limitations?
Open-label; Older drug regimens
- What does it say about Elawady's specific claim?
Supports weight/hypoglycaemia (C-INS-01); contradicts C-INS-03, C-INS-05, C-DIAB-01.
- Do the results apply to Germany and Europe?
UK; directly relevant.
- What can explicitly not be concluded from this study?
That insulin is harmful overall.
-
International guideline on diabetic ketoacidosis
Umpierrez GE et al.. Diabetes Care 2024 · PMID 39052901 · DOI 10.2337/dci24-0032Guideline / position statementindependent cross-checkfull text checked★ key studyInsulin, fluids and potassium are the core treatment; with this, fewer than 1% of adults die.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Diagnosis and management of DKA and HHS in adults
- How was the study done?
International consensus report based on systematic examination of literature since 2009 (ADA, EASD, JBDS, AACE, DTS)
- How many people, animals or samples were studied?
not applicable; Adults with diabetes
- What was actually found?
Insulin is the cornerstone; glucocorticoids worsen hyperglycaemia.
- How large was the observed effect?
Mortality <1% with treatment
- What do the results mean in everyday life?
Ketoacidosis needs hospital treatment with insulin.
- What are the study's limitations?
Consensus, not trial
- What does it say about Elawady's specific claim?
Directly contradicts C-INS-08; supports danger in C-FAST-03; contradicts C-INS-07, C-INS-10.
- Do the results apply to Germany and Europe?
EASD and JBDS (UK) co-authored; directly applicable.
- What can explicitly not be concluded from this study?
Outcomes of untreated DKA quantitatively.
-
Review: how insulin works and how insulin resistance arises
Petersen MC, Shulman GI. Physiol Rev 2018 · PMID 30067154 · DOI 10.1152/physrev.00063.2017Narrative reviewindependent cross-checkabstract checkedInsulin resistance in muscle, liver and fat is a central process in type 2 diabetes; some mechanisms are still debated.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Summarise insulin action and resistance
- How was the study done?
Narrative review
- How many people, animals or samples were studied?
Literature
- What was actually found?
Insulin resistance is a key process in type 2 diabetes
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Doctors and scientists treat insulin resistance as a real, measurable state.
- What are the study's limitations?
Narrative; abstract only
- What does it say about Elawady's specific claim?
Contradicts 'there is no such thing as insulin resistance'.
- Do the results apply to Germany and Europe?
Universal physiology
- What can explicitly not be concluded from this study?
Does not settle which mediator causes insulin resistance.
-
What happens to muscle energy when insulin is withheld in type 1 diabetes
Karakelides H et al.. Diabetes 2007 · PMID 17660267 · DOI 10.2337/db07-0378Otherindependent cross-checkabstract checked★ key studyStopping insulin for about 9 hours reduced the muscle cells' energy (ATP) production and raised ketones and protein breakdown.
Without insulin, muscle energy production falls and ketones rise.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test how insulin lack affects muscle energy production.
- How was the study done?
Insulin withdrawal vs insulin, muscle biopsies.
- How many people, animals or samples were studied?
9 adults with T1D.
- What was actually found?
Less mitochondrial ATP production, more ketones and protein loss without insulin.
- How large was the observed effect?
Not given in abstract.
- What do the results mean in everyday life?
Insulin keeps the cell's energy engine running; lack of insulin slows it.
- What are the study's limitations?
Very small study.
- What does it say about Elawady's specific claim?
Contradicts 'insulin stops the Krebs cycle'.
- Do the results apply to Germany and Europe?
Universal physiology.
- What can explicitly not be concluded from this study?
Cannot quantify long-term effects.
-
Long-term survival after intensive insulin treatment in type 1 diabetes
Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107Randomised controlled trialindependent cross-checkabstract checked★ key studyPeople who received intensive insulin treatment for about 6.5 years had about one third lower death risk 27 years later.
Intensive insulin therapy associated with lower mortality: insulin does treat diabetes.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether intensive insulin therapy affects long-term survival.
- How was the study done?
Follow-up of a randomised trial.
- How many people, animals or samples were studied?
1,441 young adults with T1D.
- What was actually found?
43 vs 64 deaths; HR 0.67.
- How large was the observed effect?
-109 deaths per 100,000 patient-years.
- What do the results mean in everyday life?
Good insulin treatment helps people with type 1 diabetes live longer.
- What are the study's limitations?
Few deaths; later years observational.
- What does it say about Elawady's specific claim?
Contradicts 'insulin does not treat diabetes'.
- Do the results apply to Germany and Europe?
Applicable to Europe.
- What can explicitly not be concluded from this study?
Cannot separate effects of later care.
-
European and US consensus 2026 on type 1 diabetes in adults
Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-zGuideline / position statementindependent cross-checkfull text checked★ key studyLifelong insulin is essential in type 1 diabetes, and everyone with type 1 diabetes should be able to test glucose and ketones.
Insulin is the essential treatment; ketosis without insulin leads to DKA.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Update guidance on adult T1D care.
- How was the study done?
Consensus report.
- How many people, animals or samples were studied?
Not applicable.
- What was actually found?
Insulin lifelong and essential; ketone testing for all.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
People with type 1 diabetes must never stop insulin.
- What are the study's limitations?
Consensus.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
European (EASD) guidance.
- What can explicitly not be concluded from this study?
Not applicable.
No study in this group is marked as key.
Studies with mixed or unclear results (3)
-
Severe low blood sugar and death in ACCORD
Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment★ key studyPeople who had severe low-sugar episodes died more often, but this did not explain why the intensive group had more deaths.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Link between severe hypoglycaemia and mortality in ACCORD
- How was the study done?
Retrospective epidemiological analysis within an RCT (ACCORD)
- How many people, animals or samples were studied?
10,194; ACCORD participants with hypoglycaemia assessment
- What was actually found?
Deaths were more common after severe low-sugar episodes (adjusted HR 1.41 and 2.30), but only 1 of 451 deaths was definitely caused by low sugar, and it explained only about 5 of 57 extra deaths in the intensive group.
- How large was the observed effect?
aHR 1.41 (1.03-1.93) intensive arm
- What do the results mean in everyday life?
Severe hypoglycaemia is a danger sign to avoid.
- What are the study's limitations?
Post-hoc observational analysis; Confounding by frailty
- What does it say about Elawady's specific claim?
Supports C-INS-04 (hypoglycaemia is a marker of risk); limits causal interpretation.
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
That hypoglycaemia caused the ACCORD excess mortality.
-
Severe hypoglycaemia in ADVANCE
Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessmentSevere low-sugar episodes were followed by more heart events and deaths, probably partly because frail people get them.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Severe hypoglycaemia and vascular events/death
- How was the study done?
Post-hoc cohort analysis of an RCT (ADVANCE)
- How many people, animals or samples were studied?
11,140; ADVANCE participants with type 2 diabetes
- What was actually found?
aHR 2.69 death.
- How large was the observed effect?
aHR 2.69 (1.97-3.67)
- What do the results mean in everyday life?
Avoid severe hypoglycaemia.
- What are the study's limitations?
Only 231 people had severe hypoglycaemia; links also seen with skin and digestive disease (suggesting frailty); no dose-response; intensive treatment was a sulfonylurea, not insulin; funded by the drug's manufacturer.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
Causation.
-
Injecting insulin into thickened fat
Famulla S et al.. Diabetes Care 2016 · PMID 27411698 · DOI 10.2337/dc16-0610Randomised controlled trialcited by the Tayebat archiveabstract checkedInsulin injected into lumpy fat tissue works less and less predictably.
Does the study support the specific claim? Unclear · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Insulin absorption from lipohypertrophic tissue
- How was the study done?
Randomised crossover clamp and meal study
- How many people, animals or samples were studied?
13; Type 1 diabetes with lipohypertrophy
- What was actually found?
Blunted, variable absorption.
- How large was the observed effect?
Insulin AUC -21%
- What do the results mean in everyday life?
Rotate injection sites.
- What are the study's limitations?
Small n
- What does it say about Elawady's specific claim?
Peripheral; shows correct injection technique matters.
- Do the results apply to Germany and Europe?
German study.
- What can explicitly not be concluded from this study?
That insulin is harmful.
No study in this group is marked as key.
Regional context
Germany / EU
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
Egypt
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
What applies in my country?
General scientific assessment
Mostly false Some cells take up glucose without insulin, but this does not make insulin therapy useless or harmful.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.. Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742976
- Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.. Umpierrez GE et al.. Diabetes Care 2024 · PMID 39052901 · DOI 10.2337/dci24-0032
- Mechanisms of Insulin Action and Insulin Resistance.. Petersen MC, Shulman GI. Physiol Rev 2018 · PMID 30067154 · DOI 10.1152/physrev.00063.2017
- Effect of insulin deprivation on muscle mitochondrial ATP production and gene transcript levels in type 1 diabetic subjects.. Karakelides H et al.. Diabetes 2007 · PMID 17660267 · DOI 10.2337/db07-0378
- Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.. Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107
- The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).. Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z
- The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.. Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
- Severe hypoglycemia and risks of vascular events and death.. Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795
- Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control.. Famulla S et al.. Diabetes Care 2016 · PMID 27411698 · DOI 10.2337/dc16-0610